Does the "Chief Scientific Officer of JDRF" have a CLUE about the day to day life of a person with type 1 diabetes? I am aghast and disgusted at his quote in this article! There are so many aspects of type 1 that are far worse than the simple injection of the insulin. My son will NOT inhale insulin. January 27, 2006 Pfizer Wins F.D.A. Approval for Inhaled Form of Insulin By ANDREW POLLACK and ALEX BERENSON An inhaled form of insulin won federal approval today, offering the first alternative to injections for millions of people with diabetes since the drug was introduced in the 1920's. The product, which will be sold by Pfizer, could offer more convenience and less pain, though not necessarily better treatment of the disease, for many of the roughly five million people already using insulin, diabetes experts say. But it could also have a big impact on public health by prompting more of the nation's estimated 21 million diabetics to start using insulin, thereby better controlling their blood sugar and reducing the risk of complications from the disease. "The thing that people with diabetes who have to take insulin hate the most are shots," said Robert Goldstein, chief scientific officer of the Juvenile Diabetes Research Foundation International. "So anything that can replace shots patients are going to be very pleased to have." Pfizer's product, Exubera, uses a powdered form of insulin and a special inhalation device initially developed by Nektar Therapeutics, a biotechnology company in San Carlos, Calif., south of San Francisco. Pfizer, which said the product should be available in the middle of the year, has not announced a price for it, though drug industry analysts expect it will be two or three times as expensive as injected insulin. Exubera was approved for use by adults with either type 1 or type 2 diabetes and is designed to be used at mealtimes. Most people with type 1 diabetes and some with type 2 will still need to take one or two injections of longer-acting insulin every day. Development of Exubera was delayed for years because of safety concerns, primarily a slight loss of lung function among people who used the product in clinical trials. Deciding whether to approve the inhaled insulin presented a challenge for the Food and Drug Administration, which has been under criticism for allowing some unsafe drugs, like Vioxx, on the market. But an advisory panel to the agency recommended approval of Exubera in September, at least for patients without pre-existing lung diseases and the agency itself, after putting off a decision for three months, concurred. "I think that we and the advisory committees felt that there was very robust data with regard to the safety of the drug in patients without underlying lung disease," Dr. Robert Meyer, director of the F.D.A. office overseeing diabetes drugs, said in a telephone news conference this afternoon. But some experts say the risks of using the product day after day for life have not been ascertained. Because of the safety questions, Exubera was not extensively tested in children and is not approved for them. It is also not recommended for those with asthma, bronchitis or emphysema. Also, smokers or those who have quit smoking within the previous six months are not supposed to use the product because their lungs absorb too much of it, posing the risk of a dangerous overdose. The agency is also recommending that people who use Exubera have their lung function checked before they start on the drug and every six to 12 months afterwards.